TipRanks
Advertisement
Advertisement

HK:9926 Stock Latest News

Akeso’s New AK157D1 Trial Signals Fresh Oncology Upside for Investors
Company AnnouncementsAkeso’s New AK157D1 Trial Signals Fresh Oncology Upside for Investors
7d ago
9926
Akeso’s Phase 3 Gastric Cancer Trial Pits Cadonilimab Against Nivolumab-Based Care
PremiumCompany Announcements
Akeso’s Phase 3 Gastric Cancer Trial Pits Cadonilimab Against Nivolumab-Based Care
7d ago
9926
Akeso’s Ivonescimab Tops Pembrolizumab in Key Lung Cancer Survival Trial
PremiumCompany Announcements
Akeso’s Ivonescimab Tops Pembrolizumab in Key Lung Cancer Survival Trial
1M ago
Akeso Narrows Interim Loss as Revenue Jumps Nearly 28%
PremiumCompany Announcements
Akeso Narrows Interim Loss as Revenue Jumps Nearly 28%
1M ago
Akeso Initiated at Buy on Breakthrough Ivonescimab Phase 3 BTC Data and Multibillion-Dollar Upside Potential
PremiumRatings
Akeso Initiated at Buy on Breakthrough Ivonescimab Phase 3 BTC Data and Multibillion-Dollar Upside Potential
1M ago
Akeso’s Ivonescimab Delivers Phase III Survival Gain in Biliary Tract Cancer
PremiumCompany AnnouncementsAkeso’s Ivonescimab Delivers Phase III Survival Gain in Biliary Tract Cancer
1M ago
Akeso Schedules Board Meeting to Approve 2026 Interim Results
Premium
Company Announcements
Akeso Schedules Board Meeting to Approve 2026 Interim Results
2M ago
Summit says Akeso receives marketing authorization in China for ivonescimab
Premium
The Fly
Summit says Akeso receives marketing authorization in China for ivonescimab
2M ago
SMMT
Akeso Wins Third NMPA Nod for Ivonescimab in Advanced Lung Cancer
PremiumCompany Announcements
Akeso Wins Third NMPA Nod for Ivonescimab in Advanced Lung Cancer
2M ago
Akeso Advances AK138D1 Lung Cancer Trial, Keeping Pipeline Momentum in Focus
PremiumCompany Announcements
Akeso Advances AK138D1 Lung Cancer Trial, Keeping Pipeline Momentum in Focus
2M ago
9926
Akeso Grants New Share Options to Boost Long-Term Incentives
PremiumCompany Announcements
Akeso Grants New Share Options to Boost Long-Term Incentives
2M ago
Akeso’s New Phase II Breast Cancer Trial Signals Fresh Upside Potential
PremiumCompany Announcements
Akeso’s New Phase II Breast Cancer Trial Signals Fresh Upside Potential
3M ago
9926
Akeso’s New Phase II Lung Cancer Trial: What Investors Should Watch
PremiumCompany AnnouncementsAkeso’s New Phase II Lung Cancer Trial: What Investors Should Watch
3M ago
9926
Akeso’s AK104 Kidney Cancer Trial Completion: What Investors Should Watch Next
Premium
Company Announcements
Akeso’s AK104 Kidney Cancer Trial Completion: What Investors Should Watch Next
3M ago
9926
Akeso Shareholders Approve All Resolutions at 2026 AGM, Renewing Board Mandates and Capital Powers
Premium
Company Announcements
Akeso Shareholders Approve All Resolutions at 2026 AGM, Renewing Board Mandates and Capital Powers
3M ago
Akeso’s Ebronucimab Manufacturing Study Reaches Completion, Trimming Risk in a Crowded Cholesterol Market
PremiumCompany Announcements
Akeso’s Ebronucimab Manufacturing Study Reaches Completion, Trimming Risk in a Crowded Cholesterol Market
3M ago
9926
Akeso Wins China NMPA Approval for IL-17 Antibody Gumokimab in Psoriasis
PremiumCompany Announcements
Akeso Wins China NMPA Approval for IL-17 Antibody Gumokimab in Psoriasis
4M ago
Akeso Launches HK$200 Million Share Purchase as Leadership Boosts Stakes
PremiumCompany Announcements
Akeso Launches HK$200 Million Share Purchase as Leadership Boosts Stakes
4M ago
Akeso’s AK104 Lung Cancer Trial Completion: What Investors Should Watch Next
PremiumCompany Announcements
Akeso’s AK104 Lung Cancer Trial Completion: What Investors Should Watch Next
4M ago
9926
Akeso Sets 2026 AGM to Approve Accounts, Board Slate and Capital-Issuance Mandate
PremiumCompany AnnouncementsAkeso Sets 2026 AGM to Approve Accounts, Board Slate and Capital-Issuance Mandate
4M ago
Akeso’s ivonescimab trial at ASCO plenary signals potential new lung cancer standard
Premium
Company Announcements
Akeso’s ivonescimab trial at ASCO plenary signals potential new lung cancer standard
4M ago
Akeso: Robust FY25 Execution and Late‑Stage Oncology Pipeline Drive Upside and Higher Target Price
Premium
Ratings
Akeso: Robust FY25 Execution and Late‑Stage Oncology Pipeline Drive Upside and Higher Target Price
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >